-
Something wrong with this record ?
Risk factors for a severe disease course in children with SARS-COV-2 infection following hematopoietic cell transplantation in the pre-Omicron period: a prospective multinational Infectious Disease Working Party from the European Society for Blood and Marrow Transplantation group (EBMT) and the Spanish Group of Hematopoietic Stem Cell Transplantation (GETH) study
D. Averbuch, R. de la Camara, G. Tridello, NS. Knelange, TA. Bykova, M. Ifversen, V. Dobsinska, M. Ayas, AA. Hamidieh, H. Pichler, A. Perez-Martinez, S. Cesaro, M. Sundin, I. Badell, P. Bader, JE. Johansson, O. Mirci-Danicar, P. Sedlacek, C....
Language English Country England, Great Britain
Document type Journal Article
NLK
Free Medical Journals
from 1997 to 1 year ago
Freely Accessible Science Journals
from 1997 to 1 year ago
ProQuest Central
from 1997-01-01 to 1 year ago
Open Access Digital Library
from 1997-01-01
Health & Medicine (ProQuest)
from 1997-01-01 to 1 year ago
- MeSH
- COVID-19 * etiology MeSH
- Child MeSH
- Transplantation, Homologous MeSH
- Communicable Diseases * etiology MeSH
- Cough etiology MeSH
- Bone Marrow MeSH
- Humans MeSH
- Disease Progression MeSH
- Prospective Studies MeSH
- Risk Factors MeSH
- SARS-CoV-2 MeSH
- COVID-19 Testing MeSH
- Hematopoietic Stem Cell Transplantation * adverse effects MeSH
- Check Tag
- Child MeSH
- Humans MeSH
- Male MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
Risk factors for severe SARS-Cov-2 infection course are poorly described in children following hematopoietic cell transplantation (HCT). In this international study, we analyzed factors associated with a severe course (intensive care unit (ICU) admission and/or mortality) in post-HCT children. Eighty-nine children (58% male; median age 9 years (min-max 1-18)) who received an allogeneic (85; 96%) or an autologous (4; 4%) HCT were reported from 28 centers (18 countries). Median time from HCT to SARS-Cov-2 infection was 7 months (min-max 0-181). The most common clinical manifestations included fever (37; 42%) and cough (26; 29%); 37 (42%) were asymptomatic. Nine (10%) children following allo-HCT required ICU care. Seven children (8%) following allo-HCT, died at a median of 22 days after SARS-Cov-2 diagnosis. In a univariate analysis, the probability of a severe disease course was higher in allo-HCT children with chronic GVHD, non-malignant disease, immune suppressive treatment (specifically, mycophenolate), moderate immunodeficiency score, low Lansky score, fever, cough, coinfection, pulmonary radiological findings, and high C-reactive protein. In conclusion, SARS-Cov-2 infection in children following HCT was frequently asymptomatic. Despite this, 10% needed ICU admission and 8% died in our cohort. Certain HCT, underlying disease, and SARS-Cov-2 related factors were associated with a severe disease course.
BMT Unit Bristol Royal Hospital for Children Bristol UK
Bone Marrow Transplantation Unit National Institute of Children's Diseases Bratislava Slovakia
Department of Haematology Birmingham Children's Hospital Birmingham UK
Department of Haematology Royal Hospital for Children Glasgow UK
Department of Pediatric Hematology and Oncology Comenius University Bratislava Slovakia
Department of Pediatric Hematology and Oncology Hospital Universitario La Paz Madrid Spain
Department of Stem Cell Transplantation University Hospital Eppendorf Hamburg Germany
Division of Infectious Diseases University of Genova Ospedale Policlinco San Martino Genova Italy
EBMT Leiden Study Unit Leiden Netherlands
Hematology Department Hospital Universitario de La Princesa Madrid Spain
Pediatric BMT Unit Hospital Santa Creu i Sant Pau Universitat Autonoma de Barcelona Barcelona Spain
Pediatric Hematology Oncology Hautepierre Hospital Strasbourg University Strasbourg France
RM Gorbacheva Research Institute Pavlov University St Petersburg Russia
Sahlgrenska University Hospital Goeteborg Sweden
Universitaetsklinikum Frankfurt Goethe Universitaet Frankfurt Main Germany
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc23011592
- 003
- CZ-PrNML
- 005
- 20230801133152.0
- 007
- ta
- 008
- 230718s2023 enk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1038/s41409-023-01941-5 $2 doi
- 035 __
- $a (PubMed)36849806
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a enk
- 100 1_
- $a Averbuch, Dina $u Faculty of Medicine, Hebrew University of Jerusalem, Pediatric Infectious Diseases, Hadassah Medical Center, Jerusalem, Israel. adiana@hadassah.org.il $1 https://orcid.org/0000000196147274
- 245 10
- $a Risk factors for a severe disease course in children with SARS-COV-2 infection following hematopoietic cell transplantation in the pre-Omicron period: a prospective multinational Infectious Disease Working Party from the European Society for Blood and Marrow Transplantation group (EBMT) and the Spanish Group of Hematopoietic Stem Cell Transplantation (GETH) study / $c D. Averbuch, R. de la Camara, G. Tridello, NS. Knelange, TA. Bykova, M. Ifversen, V. Dobsinska, M. Ayas, AA. Hamidieh, H. Pichler, A. Perez-Martinez, S. Cesaro, M. Sundin, I. Badell, P. Bader, JE. Johansson, O. Mirci-Danicar, P. Sedlacek, C. Paillard, B. Gibson, S. Lawson, N. Kroeger, S. Corbacioglu, M. Mikulska, JL. Piñana, J. Styczynski, P. Ljungman
- 520 9_
- $a Risk factors for severe SARS-Cov-2 infection course are poorly described in children following hematopoietic cell transplantation (HCT). In this international study, we analyzed factors associated with a severe course (intensive care unit (ICU) admission and/or mortality) in post-HCT children. Eighty-nine children (58% male; median age 9 years (min-max 1-18)) who received an allogeneic (85; 96%) or an autologous (4; 4%) HCT were reported from 28 centers (18 countries). Median time from HCT to SARS-Cov-2 infection was 7 months (min-max 0-181). The most common clinical manifestations included fever (37; 42%) and cough (26; 29%); 37 (42%) were asymptomatic. Nine (10%) children following allo-HCT required ICU care. Seven children (8%) following allo-HCT, died at a median of 22 days after SARS-Cov-2 diagnosis. In a univariate analysis, the probability of a severe disease course was higher in allo-HCT children with chronic GVHD, non-malignant disease, immune suppressive treatment (specifically, mycophenolate), moderate immunodeficiency score, low Lansky score, fever, cough, coinfection, pulmonary radiological findings, and high C-reactive protein. In conclusion, SARS-Cov-2 infection in children following HCT was frequently asymptomatic. Despite this, 10% needed ICU admission and 8% died in our cohort. Certain HCT, underlying disease, and SARS-Cov-2 related factors were associated with a severe disease course.
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a dítě $7 D002648
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a homologní transplantace $7 D014184
- 650 _2
- $a prospektivní studie $7 D011446
- 650 _2
- $a kostní dřeň $7 D001853
- 650 _2
- $a testování na COVID-19 $7 D000086742
- 650 _2
- $a kašel $x etiologie $7 D003371
- 650 12
- $a COVID-19 $x etiologie $7 D000086382
- 650 _2
- $a SARS-CoV-2 $7 D000086402
- 650 12
- $a transplantace hematopoetických kmenových buněk $x škodlivé účinky $7 D018380
- 650 _2
- $a rizikové faktory $7 D012307
- 650 _2
- $a progrese nemoci $7 D018450
- 650 12
- $a infekční nemoci $x etiologie $7 D003141
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a de la Camara, Rafael $u Hematology Department, Hospital Universitario de La Princesa, Madrid, Spain $1 https://orcid.org/0000000281895779
- 700 1_
- $a Tridello, Gloria $u Pediatric Hematology Oncology, Department of Mother and Child, Azienda Ospedaliera Universitaria Integrata, Verona, Italy
- 700 1_
- $a Knelange, Nina Simone $u EBMT - Leiden Study Unit, Leiden, Netherlands
- 700 1_
- $a Bykova, Tatiana A $u RM Gorbacheva Research Institute, Pavlov University, St. Petersburg, Russia $1 https://orcid.org/0000000244562369
- 700 1_
- $a Ifversen, Marianne $u Department of Children and Adolescents Medicine, Stem Cell Transplant Unit, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark $1 https://orcid.org/0000000225581935
- 700 1_
- $a Dobsinska, Veronika $u Department of Pediatric Hematology and Oncology, Comenius University, Bratislava, Slovakia $u Bone Marrow Transplantation Unit, National Institute of Children's Diseases, Bratislava, Slovakia
- 700 1_
- $a Ayas, Mouhab $u Pediatric Hematology/Oncology, King Faisal Specialist Hospital and Research Centre, Riyadh, Saudi Arabia $1 https://orcid.org/0000000257401302
- 700 1_
- $a Hamidieh, Amir Ali $u Pediatric Cell and Gene Therapy Research Center, Gene, Cell & Tissue Research Institute, Tehran University of Medical Sciences, Tehran, Iran $1 https://orcid.org/000000028935079X
- 700 1_
- $a Pichler, Herbert $u Department of Pediatric Hematology and Oncology, St. Anna Children's Hospital, Department of Pediatrics and Adolescent Medicine, Medical University of Vienna, Vienna, Austria $1 https://orcid.org/0000000151075123
- 700 1_
- $a Perez-Martinez, Antonio $u Department of Pediatric Hematology and Oncology, Hospital Universitario La Paz, Madrid, Spain $1 https://orcid.org/0000000264369195
- 700 1_
- $a Cesaro, Simone $u Pediatric Hematology Oncology, Department of Mother and Child, Azienda Ospedaliera Universitaria Integrata, Verona, Italy $1 https://orcid.org/0000000286989547
- 700 1_
- $a Sundin, Mikael $u Section of Pediatric Hematology, Immunology and HCT, Astrid Lindgren Children's Hospital, Karolinska University Hospital and Division of Pediatrics, CLINTEC, Karolinska Institutet, Stockholm, Sweden
- 700 1_
- $a Badell, Isabel $u Pediatric BMT Unit, Hospital Santa Creu i Sant Pau, Universitat Autonoma de Barcelona, Barcelona, Spain
- 700 1_
- $a Bader, Peter $u Universitaetsklinikum Frankfurt Goethe-Universitaet, Frankfurt Main, Germany $1 https://orcid.org/0000000345540265
- 700 1_
- $a Johansson, Jan-Erik $u Sahlgrenska University Hospital, Goeteborg, Sweden
- 700 1_
- $a Mirci-Danicar, Oana $u BMT Unit, Bristol Royal Hospital for Children, Bristol, UK
- 700 1_
- $a Sedlacek, Petr $u HSCT Unit, Department of Paediatric Haematology and Oncology, University Hospital Motol, Prague, Czech Republic $1 https://orcid.org/0000000178952886 $7 xx0037062
- 700 1_
- $a Paillard, Catherine $u Pediatric Hematology Oncology, Hautepierre Hospital, Strasbourg University, Strasbourg, France
- 700 1_
- $a Gibson, Brenda $u Department of Haematology, Royal Hospital for Children, Glasgow, UK
- 700 1_
- $a Lawson, Sarah $u Department of Haematology, Birmingham Children's Hospital, Birmingham, UK
- 700 1_
- $a Kroeger, Nicolaus $u Department of Stem Cell Transplantation, University Hospital Eppendorf, Hamburg, Germany $1 https://orcid.org/0000000151039966
- 700 1_
- $a Corbacioglu, Selim $u Department of Pediatric Hematology, Oncology and Stem Cell Transplantation, University of Regensburg, Regensburg, Germany
- 700 1_
- $a Mikulska, Malgorzata $u Division of Infectious Diseases, University of Genova, Ospedale Policlinco San Martino, Genova, Italy $1 https://orcid.org/0000000255354602
- 700 1_
- $a Piñana, Jose Luis $u Hospital Clinico Universitario de Valencia. Fundación de investigación INCLIVA, Hospital Clinico Universitario de Valencia, Valencia, Spain $1 https://orcid.org/0000000185332562
- 700 1_
- $a Styczynski, Jan $u Pediatric Hematology and Oncology, University Hospital, Collegium Medicum, Nicolaus Copernicus University Torun, Bydgoszcz, Poland $1 https://orcid.org/000000023158119X
- 700 1_
- $a Ljungman, Per $u Department of Cellular Therapy and Allogeneic Stem Cell Transplantation, Karolinska Comprehensive Cancer Center, Karolinska University Hospital Huddinge, Division of Hematology, Department of Medicine Huddinge, Karolinska Institutet, Stockholm, Sweden $1 https://orcid.org/0000000282813245 $7 xx0224650
- 773 0_
- $w MED00000834 $t Bone marrow transplantation $x 1476-5365 $g Roč. 58, č. 5 (2023), s. 558-566
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/36849806 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y p $z 0
- 990 __
- $a 20230718 $b ABA008
- 991 __
- $a 20230801133148 $b ABA008
- 999 __
- $a ok $b bmc $g 1963804 $s 1197857
- BAS __
- $a 3
- BAS __
- $a PreBMC-MEDLINE
- BMC __
- $a 2023 $b 58 $c 5 $d 558-566 $e 20230227 $i 1476-5365 $m Bone marrow transplantation $n Bone Marrow Transplant $x MED00000834
- LZP __
- $a Pubmed-20230718
